Trends in Neoadjuvant Approaches in Pancreatic Cancer
- 7 August 2017
- journal article
- review article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 15 (8), 1070-1077
- https://doi.org/10.6004/jnccn.2017.0134
Abstract
Pancreatic cancer (PDAC) is an aggressive tumor type associated with development of micrometastasis at an early stage. In attempt to eradicate disseminated disease, neoadjuvant therapy has been explored in patients with resectable and borderline resectable PDAC. In large retrospective studies, neoadjuvant therapy was associated with better survival compared with upfront surgery. Previously, trials more commonly used radiotherapy (RT) with small doses of chemotherapy as radiosensitizers. Recent studies, however, have incorporated full systemic doses of chemotherapy with or without RT before surgery with the hope of achieving adequate systemic chemotherapy coverage and improving survival. Several phase II trials have shown encouraging clinical benefits using the neoadjuvant approach. Large cooperative group studies are exploring the role of neoadjuvant treatment with newer combination chemotherapy regimens and modern RT techniques, which will provide more evidence regarding the utility of this approach.This publication has 20 references indexed in Scilit:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineThe New England Journal of Medicine, 2013
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJama-Journal Of The American Medical Association, 2013
- A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancerCancer, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic AdenocarcinomaAmerican Journal of Clinical Oncology, 2008
- Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic HeadJournal of Clinical Oncology, 2008
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic HeadJournal of Clinical Oncology, 2008
- Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic HeadJournal of Clinical Oncology, 2008
- A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with CisplatinAnnals of Surgical Oncology, 2007